DDIs between corticosteroids and cobicistat or ritonavir

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2019年 / 1766卷 / 1期
关键词：
D O I：
10.1007/s40278-019-66078-4
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：6 / 6
相关论文
共 50 条
  • [41] Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient
    Andrea Erba
    Catia Marzolini
    Katharina Rentsch
    Marcel Stoeckle
    Manuel Battegay
    Michael Mayr
    Maja Weisser
    Virology Journal, 20
  • [42] STRIBILD™ (EMTRICITABINE/TENOFOVIR/ELVITEGRAVIR/COBICISTAT) AND DARUNAVIR: A NOVEL REGIMEN FOR THE PI EXPERIENCED, RITONAVIR INTOLERANT PATIENT
    Page, Matthew
    Barrett, Sarah
    Taylor, Steve
    SEXUALLY TRANSMITTED INFECTIONS, 2015, 91 : A29 - A29
  • [43] Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications
    Marzolini, Catia
    Gibbons, Sara
    Khoo, Saye
    Back, David
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (07) : 1755 - 1758
  • [44] Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results
    Gallant, Joel E.
    Koenig, Ellen
    Andrade-Villanueva, Jaime F.
    Chetchotisakd, Ploenchan
    DeJesus, Edwin
    Antunes, Francisco
    Arasteh, Keikawus
    Rizzardini, Giuliano
    Fehr, Jan
    Liu, Hui C.
    Abram, Michael E.
    Cao, Huyen
    Szwarcberg, Javier
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 69 (03) : 338 - 340
  • [45] Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient
    Erba, Andrea
    Marzolini, Catia
    Rentsch, Katharina
    Stoeckle, Marcel
    Battegay, Manuel
    Mayr, Michael
    Weisser, Maja
    VIROLOGY JOURNAL, 2023, 20 (01)
  • [46] Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
    Moore, Katy
    Thakkar, Nilay
    Magee, Mindy
    Sevinsky, Heather
    Vakkalagadda, Blisse
    Lubin, Susan
    Llamoso, Cyril
    Ackerman, Peter
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (04)
  • [47] Cost-effectiveness switching from ritonavir-to cobicistat-boosted PIs: is simplification as straightforward as it sounds?
    Colver, H.
    Sobo, T.
    Turner, J.
    HIV MEDICINE, 2018, 19 : S23 - S23
  • [48] The importance of awareness of ritonavir / cobicistat CYP 34A enzyme inhibition and its effect on steroid metabolism.
    McDonnell, T. M.
    Baldeweg, S. E.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 : S373 - S373
  • [49] Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran
    Kakadiya, Payal P.
    Higginson, Robert T.
    Fulco, Patricia Pecora
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (02)
  • [50] Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy
    Mena, Alvaro
    Cid, Purificacion
    Duenas, Carlos
    Angeles Garcinuno, Maria
    Francisco Lorenzo, Juan
    Margusino, Luis
    Quinones, Marina
    Grande, Carmen
    Rodriguez-Osorio, Iria
    Castro, Angeles
    HIV CLINICAL TRIALS, 2018, 19 (05): : 197 - 201
12345